Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that members of Aura’s executive team will participate in the following upcoming investor conferences:
Canaccord Genuity’s 39th Annual Growth Conference on August 8, 2019 in Boston, MA and will present at 2:00 p.m. Eastern Time
BTIG Biotechnology Conference on August 12, 2019 in New York, NY
Aura Biosciences announced that two-year clinical data from its ongoing Phase 1b/2 clinical trial evaluating the safety and efficacy of light-activated AU-011, the Company’s lead product candidate for the treatment of primary choroidal melanoma, will be highlighted in an oral presentation at the 37th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held July 26- 30, 2019 in Chicago, Illinois.
Molecular Cancer Therapeutics
Kines R, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin R, Kang S, Grossniklaus H, Vavvas D, Monks S, MacDougall J, de los Pinos E, Schiller J
Kaliki S and Shields C L